The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intra-treatment hypoxia directed major radiation de-escalation as definitive treatment for human papillomavirus-related oropharyngeal cancer.
 
NANCY Y. LEE
Consulting or Advisory Role - Elsie Pharmaceuticals; Galera Therapeutics; Merck; Merck Serono; Mirati Therapeutics; Nanobiotix; Regeneron
Speakers' Bureau - Shanghai Joanne Medical LTD; Varian Medical Systems; Yingming Consulting
 
Eric Jeffrey Sherman
Consulting or Advisory Role - AffyImmune Therapeutics; Blueprint Medicines; Eisai; Exelixis; Lilly; UpToDate
Research Funding - Fore Biotherapeutics (Inst); HUTCHMED (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst)
 
Heiko Schöder
No Relationships to Disclose
 
Rick Wray
No Relationships to Disclose
 
Charlie White
No Relationships to Disclose
 
Lara Dunn
Consulting or Advisory Role - Merck
Research Funding - CUE Biopharma; Nektar; Regeneron; Replimune; Seagan; Seagan
 
Tony Hung
No Relationships to Disclose
 
David G. Pfister
Consulting or Advisory Role - MeiraGTx; Nykode Therapeutics
Research Funding - Akeso Biopharma; AstraZeneca (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Eisai (Inst); Hookipa Pharma (Inst); Lilly (Inst); MedImmune (Inst); MeiraGTx (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
Alan Loh Ho
Stock and Other Ownership Interests - Rgenta
Honoraria - Chinese American Hematology and Oncology Network; Endocrine Society (Clinical Endocrinology Update); Physicans' Education Resource
Consulting or Advisory Role - AffyImmune Therapeutics; Cellestia Biotech; Coherus Biosciences; Eisai; Eisai; Elevar Therapeutics; Exelixis; ExpertConnect; InxMed; Kura Oncology; Merck; Nested Therapeutics; Prelude Therapeutics; Remix Therapeutics; Rgenta
Research Funding - Astellas Pharma; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bayer; BioAtla; Bristol-Myers Squibb; Eisai; Elevar Therapeutics; Elevar Therapeutics; Genentech/Roche; Kura Oncology; Merck; Novartis; OncC4; Poseida; TILT Biotherapeutics; Verastem
Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN
 
Sean Matthew McBride
Consulting or Advisory Role - AstraZeneca; Janssen
Research Funding - AstraZeneca; Genentech
 
Yao Yu
Research Funding - EMD Serono (Inst)
Patents, Royalties, Other Intellectual Property - Springer Author Royalties; Springer Author Royalties
 
Kaveh Zakeri
Consulting or Advisory Role - EMD Serono
 
Noah Kalman
No Relationships to Disclose
 
Charles Rutter
No Relationships to Disclose
 
Luc Morris
Patents, Royalties, Other Intellectual Property - I am an inventor on IP owned by Memorial Sloan Kettering Cancer Center and licensed to PGDx
 
Bhuvanesh Singh
Employment - Memorial Sloan-Kettering Cancer Center; New York University (NYU) (I)
Consulting or Advisory Role - CinR
Patents, Royalties, Other Intellectual Property - Methods and composition of inhibiting DCN1-UBC12 interaction. (US patent, 9,447,156, 9/20/16) (Inst); Methods and compositions of inhibiting DCN1-UBC12 interaction. (United States Patent 10,525,048; 1/7/20; United States Patent 11,116,757; 9/14/21 (Inst)
 
Jay Boyle
No Relationships to Disclose
 
Ian Ganly
No Relationships to Disclose
 
Richard J. Wong
No Relationships to Disclose
 
Nadeem Riaz
Honoraria - Oxford university press; PeerView
Consulting or Advisory Role - Mirati Therapeutics; Repare Therapeutics
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Paige.AI; Pfizer; Repare Therapeutics
Travel, Accommodations, Expenses - Varian Medical Systems